DUR Committee

March 15th 2013 Minutes

Members Present:
Chuck Semling, PharmD
John Pappenheim, MD - Telephonic
Rader, Maggi, CNM
Greg Salard, MD
C.J. Kim, R.Ph (DHSS)
Erin Narus, Pharm.D. (Magellan)

Members Absent:
Dharna Begich, Pharm.D.
Jenny Love, MD

Public attendees:
Jim Graves - BMS

- Meeting started at 1:02pm and attendance was taken.
- Review of minutes from February 18, 2013 meeting. (Approved)
- Comments from C.Kim regarding previously approved Lyrica TD/QL edit. Instructions to the call center have been made to allow for a taper/titration override when requested by a pharmacist or physician. The call center is capable of notifying the provider of approvals to allow for a taper and/or titration therapy.
- Review agenda for additions, no changes or additions

ProDUR

- Proposed Prior Authorization: Marinol (dronabinol) – Tabled from January 18, 2013 meeting
  - Letters were sent out to 51-providers asking for their comments regarding proposed Marinol-PA
    - Only 2-providers responded via email with their comments for the committee to review
    - Members discussed feedback from the two providers
      - Amend proposal to add 'nausea' to the anorexia associated…
      - Not add COPD under criteria for approval
      - No change to quantity limits
    - UNANIMOUSLY APPROVED with amendment
- Proposed Prior Authorization H.P. Acthar Gel
  - C.Kim presented some background information regarding the medication and claims history
  - Discussion about indication, and place in therapy
    - UNANIMOUSLY APPROVED
- Proposed Exalgo Prior Authorization and Revised Quantity Limits
  - C.Kim presented some background information regarding the medication
  - Discussion regarding providing a cost comparison of drug classes. If it was available it might help educate physicians about the newer medications cost and let them realize that there may be substantial savings using alternative therapies that have generics
  - The revised Quantity Limits were more appropriate
    - UNANIMOUSLY APPROVED PA with REVISED QL
- Proposed Ophthalmics for Allergic Conjunctivitis – Quantity Limits, Day Supply Edit AND Proposed Intranasal Medications for Allergic – Quantity Limits, Day Supply Edit
  - Many of the eye and intranasal products for allergies are prepackaged to be a 30 day supply of medication if taken at the recommended and approved dosing (from the package insert)
  - Discussed at the same time; claims history is revealing that some pharmacies are not correctly calculating the day supply of the product whether it be a computer/human error or not verifying with the prescriber the recommended dosing of the medication

        - Editing on the minimum days supply should prevent an incorrect day supply. Incorrect days supply could potentially lead to the medication being refilled early and create an opportunity of stock piling or 'sharing'.
        - Creating a rolling limit should help pharmacies identify that when the product maybe being over-used. This can create an opportunity for the pharmacist to intervene by consulting with the patient to find out if they do not understand the dosing therapy or proper usage of the medication. If necessary the pharmacist could contact the physician with questions regarding the therapy
        - BOTH UNANIMOUSLY APPROVED with DAY SUPPLY EDIT
- Proposed Xarelto Prior Authorization – Revised
    - Product was reviewed at the September 21, 2012 DUR meeting and tabled for a future meeting
    - Currently the Medicaid Program has other similar products on PA and another one has been recently approved
    - The Medicaid call center has seen an increase amount of claims and would like more clarity on the PA approval process
    - Xarelto has received additional indications (Nov 2012) for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and for the reduction in the recurrence of DVT and PE
        - UNANIMOUSLY APPROVED
- New Prescription Medications (Interim PA List) – 6 Month Review
    - C.Kim presented information and claim details for the medications on list
        - Remove from Interim PA List:
            - Codeine sulfate oral solution 30mg/5mL
            - Angeliq 0.25mg/0.5mg
            - Ketodan Foam & Kit 2%
            - Benzepro 5.3% & 9.8%
            - Pertzye DR 8,000 & 16,000
            - Combivent Respimat
        - Leave on Interim PA List:
            - Dymista
            - Zetonna
            - Hecoria
            - Sklice
            - Ciclodan Cream Kit
            - Ultravate X Cream & Ultravate X Oint
            - Glutmetza ER 1000mg
        - UNANIMOUSLY APPROVED

Retrospective DUR

- Discuss review criteria
    - Retrospective DUR (serotonergic agents with serotonergic agents)
    - The profiles were discussed and evaluated for intervention letters to be sent out to the providers.
        - Interventions discussed on profiles varied from polypharmacy, polyprovider, therapeutic duplication, over-utilization, high-dose, drug-drug interactions, candidates for possible "lock-ins", and unnecessary care/duration.
        - Explain that when reviewing the profiles and letters should be sent out, also consider the possibility about edits that may be implemented to prevent or educate about drug-drug interactions or dosing availabilities (dose optimization)
    - Presented information on previous implemented edits and removal of PA's:

        - History Edit of Inhalers; Feb 2013
        - Hepatitis C (Protease Inhibitors); PA Feb 2012
        - Xyrem Claims History
        - Revia (naltrexone) claims history; PA removed 5/2/2012
        - Flector Patch claims history; QL Apr 2012
    - New FDA safety alerts discussed: Azithromycin – Risk of Potentially Fatal Heart Rhythms
    - New business about future PA's and some general information of how the system functions
- Comments/Suggestions:
    - Replace current information on PDMP with new FDA safety alerts like: Information on new recommend zolpidem dosing and Azithromycin recipients with risk factors
    - Work on drug cost comparisons
    - Creating a type of newsletter on drug information, correct billing procedures, and maybe add a section for cost comparisons
    - C.Kim suggested to committee members to submit informational websites they use in their practice. Will add websites on intervention letters to pass on educational information to providers about new drugs, therapies, or in general to pass on useful information
- Next meeting is scheduled for April 19, 2013 and location same as before.
- Meeting adjourned 3:30pm.